interactions:
- request:
    body: null
    headers:
      Accept:
      - '*/*'
      Accept-Encoding:
      - gzip, deflate
      Connection:
      - keep-alive
      User-Agent:
      - python-requests/2.25.1
    method: GET
    uri: https://web.expasy.org/cellosaurus/CVCL_0395.txt
  response:
    body:
      string: '<pre>ID   LNCaP

        AC   CVCL_0395

        SY   LNCAP; LNCap; Ln-Cap; Lymph Node Carcinoma of the prostate

        DR   BTO; BTO:0001321

        DR   CLO; CLO_0007365

        DR   EFO; EFO_0002071

        DR   MCCL; MCC:0000290

        DR   CLDB; cl3243

        DR   ArrayExpress; E-MTAB-2706

        DR   BioSample; SAMN03472386

        DR   CCRID; 3111C0001CCC000040

        DR   CCTCC; GDC0283

        DR   CCTCC; GDC0284

        DR   ChEMBL-Cells; CHEMBL3307965

        DR   ChEMBL-Targets; CHEMBL612518

        DR   CLS; 300265/p761_LNCaP

        DR   Cosmic; 704848

        DR   Cosmic; 721368

        DR   Cosmic; 721555

        DR   Cosmic; 755298

        DR   Cosmic; 759895

        DR   Cosmic; 801348

        DR   Cosmic; 850413

        DR   Cosmic; 850745

        DR   Cosmic; 850821

        DR   Cosmic; 869155

        DR   Cosmic; 918500

        DR   Cosmic; 920967

        DR   Cosmic; 921047

        DR   Cosmic; 922553

        DR   Cosmic; 923955

        DR   Cosmic; 943176

        DR   Cosmic; 948076

        DR   Cosmic; 949248

        DR   Cosmic; 1028648

        DR   Cosmic; 1028701

        DR   Cosmic; 1066237

        DR   Cosmic; 1070886

        DR   Cosmic; 1071481

        DR   Cosmic; 1071906

        DR   Cosmic; 1075275

        DR   Cosmic; 1172626

        DR   Cosmic; 1176618

        DR   Cosmic; 1330909

        DR   Cosmic; 1556120

        DR   Cosmic; 1689708

        DR   Cosmic; 1995486

        DR   Cosmic; 2537792

        DR   Cosmic; 2580128

        DR   Cosmic; 2585151

        DR   Cosmic; 2585228

        DR   Cosmic; 2621168

        DR   Cosmic; 2651770

        DR   Cosmic; 2669169

        DR   Cosmic; 2816221

        DR   DSMZ; ACC-256

        DR   GEO; GSE99795

        DR   GEO; GSM91927

        DR   GEO; GSM482669

        DR   GEO; GSM525800

        DR   GEO; GSM784790

        DR   GEO; GSM816637

        DR   GEO; GSM816634

        DR   GEO; GSM844579

        DR   GEO; GSM945240

        DR   GEO; GSM945282

        DR   GEO; GSM1029460

        DR   GEO; GSM1029461

        DR   GEO; GSM1029462

        DR   GEO; GSM1029463

        DR   GEO; GSM1029464

        DR   GEO; GSM1029465

        DR   GEO; GSM1029466

        DR   GEO; GSM1029467

        DR   GEO; GSM1374622

        DR   GEO; GSM1374626

        DR   GEO; GSM2069518

        DR   GEO; GSM2069519

        DR   GEO; GSM2069520

        DR   GEO; GSM2069521

        DR   GEO; GSM2069522

        DR   GEO; GSM2069523

        DR   GEO; GSM2069524

        DR   GEO; GSM2069525

        DR   IARC_TP53; 21076

        DR   LINCS_LDP; LCL-1298

        DR   Lonza; 109

        DR   PharmacoDB; LNCAP_850_2019

        DR   PRIDE; PXD000953

        DR   PRIDE; PXD000985

        DR   PRIDE; PXD002107

        DR   PRIDE; PXD002395

        DR   PRIDE; PXD003105

        DR   PRIDE; PXD003262

        DR   Progenetix; CVCL_0395

        DR   TOKU-E; 3599

        DR   Wikidata; Q6459234

        RX   CelloPub=CLPUB00410;

        RX   PubMed=3335022;

        RX   PubMed=3518877;

        RX   PubMed=6831420;

        RX   PubMed=8687134;

        RX   PubMed=9018337;

        RX   PubMed=9090379;

        RX   PubMed=10702678;

        RX   PubMed=10972993;

        RX   PubMed=11135431;

        RX   PubMed=11172901;

        RX   PubMed=11414198;

        RX   PubMed=12725112;

        RX   PubMed=14518029;

        RX   PubMed=15162376;

        RX   PubMed=15486987;

        RX   PubMed=22213130;

        RX   PubMed=22278370;

        RX   PubMed=23671654;

        RX   PubMed=24587179;

        RX   PubMed=24618588;

        RX   PubMed=25485619;

        RX   PubMed=26256267;

        RX   PubMed=26972028;

        RX   PubMed=27036029;

        RX   PubMed=27141528;

        RX   PubMed=29233929;

        RX   PubMed=29660373;

        RX   PubMed=30787054;

        WW   http://lncap.com/

        WW   https://en.wikipedia.org/wiki/LNCaP

        WW   http://141.61.102.20/mxdb/project/show/9191407937500

        WW   http://genome.ucsc.edu/ENCODE/protocols/cell/human/LNCaP_Crawford_protocol.pdf

        WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/l/cell-lines-detail-136.html

        CC   Group: Space-flown cell line (cellonaut).

        CC   Part of: ENCODE project common cell types; tier 3.

        CC   Doubling time: ~60 hours (DSMZ).

        CC   Microsatellite instability: Instable (MSI) (PubMed=23671654).

        CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G);
        ClinVar=VCV000009831; Zygosity=Hemizygous (PubMed=22213130).

        CC   Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G)
        (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from
        child cell line LNCaP clone FGC).

        CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter
        (c.1915C>T); Zygosity=Heterozygous (from child cell line LNCaP clone FGC).

        CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4
        (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (PubMed=9090379).

        CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=-
        (PubMed=14518029).

        CC   Omics: Array-based CGH.

        CC   Omics: Deep exome analysis.

        CC   Omics: Deep phosphoproteome analysis.

        CC   Omics: Deep proteome analysis.

        CC   Omics: Deep RNAseq analysis.

        CC   Omics: Glycoproteome analysis by proteomics.

        CC   Omics: GPI-anchored proteins analysis by proteomics.

        CC   Omics: H3K4me3 ChIP-seq epigenome analysis.

        CC   Omics: SNP array analysis.

        CC   Omics: Transcriptome analysis.

        CC   Omics: Virome analysis using proteomics.

        CC   Derived from metastatic site: Left supraclavicular lymph node.

        ST   Source(s): CCRID; CLS; DSMZ; PubMed=11416159; PubMed=14518029; PubMed=25877200

        ST   Amelogenin: X (CLS)

        ST   Amelogenin: X,Y (CCRID; DSMZ; PubMed=11416159; PubMed=14518029; PubMed=25877200)

        ST   CSF1PO: 10,11

        ST   D13S317: 10,11,12,13 (PubMed=14518029)

        ST   D13S317: 10,12 (CCRID; CLS; PubMed=25877200)

        ST   D16S539: 11

        ST   D18S51: 9,11,12 (CCRID)

        ST   D18S51: 11,12 (CLS; PubMed=14518029; PubMed=25877200)

        ST   D19S433: 13.2,15

        ST   D21S11: 28,29,31.2 (PubMed=25877200)

        ST   D21S11: 29,31.2 (CLS)

        ST   D21S11: 29,31.2,32.2 (PubMed=11416159)

        ST   D21S11: 29,32.2 (CCRID; PubMed=14518029)

        ST   D2S1338: 16,17

        ST   D3S1358: 16

        ST   D5S818: 11,12 (CCRID; CLS; DSMZ; PubMed=14518029)

        ST   D5S818: 11,12,13 (PubMed=25877200)

        ST   D7S820: 8.1,9.1,10.3 (CCRID; PubMed=25877200)

        ST   D7S820: 9,11 (PubMed=14518029)

        ST   D7S820: 9.1,10.3 (CLS; DSMZ)

        ST   D8S1179: 12,13,14 (PubMed=11416159)

        ST   D8S1179: 12,14 (CCRID; CLS; PubMed=14518029; PubMed=25877200)

        ST   FGA: 19,20 (CCRID; CLS; PubMed=14518029; PubMed=25877200)

        ST   FGA: 19,20,21 (PubMed=11416159)

        ST   Penta D: 12,12.4

        ST   Penta E: 12,16 (CLS)

        ST   Penta E: 16 (PubMed=25877200)

        ST   TH01: 9

        ST   TPOX: 8,9

        ST   vWA: 16,18

        DI   NCIt; C4863; Prostate carcinoma

        OX   NCBI_TaxID=9606; ! Homo sapiens

        SX   Male

        AG   50Y

        CA   Cancer cell line

        DT   Created: 04-04-12; Last updated: 20-05-21; Version: 33

        //

        RX   CelloPub=CLPUB00410;

        RA   Horoszewicz J.S., Leong S.S., Chu T.M., Wajsman A., Friedman M.,

        RA   Papsidero L.D., Kim U., Chai L.S., Kakati S., Arya S.K., Sandberg A.A.;

        RT   "The LNCaP cell line -- a new model for studies on human prostatic

        RT   carcinoma.";

        RL   (In) Models for prostate cancer; Murphy G.P. (eds.); pp.115-132; Alan
        R. Liss; New York (1980).

        //

        RX   PubMed=3335022;

        RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,

        RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;

        RT   "Feasibility of drug screening with panels of human tumor cell lines

        RT   using a microculture tetrazolium assay.";

        RL   Cancer Res. 48:589-601(1988).

        //

        RX   PubMed=3518877; DOI=10.3109/07357908609038260;

        RA   Fogh J.;

        RT   "Human tumor lines for cancer research.";

        RL   Cancer Invest. 4:157-184(1986).

        //

        RX   PubMed=6831420;

        RA   Horoszewicz J.S., Leong S.S., Kawinski E., Karr J.P., Rosenthal H.,

        RA   Chu T.M., Mirand E.A., Murphy G.P.;

        RT   "LNCaP model of human prostatic carcinoma.";

        RL   Cancer Res. 43:1809-1818(1983).

        //

        RX   PubMed=8687134;

        RA   Pandalai P.K., Pilat M.J., Yamazaki K., Naik H., Pienta K.J.;

        RT   "The effects of omega-3 and omega-6 fatty acids on in vitro prostate

        RT   cancer growth.";

        RL   Anticancer Res. 16:815-820(1996).

        //

        RX   PubMed=9018337; DOI=10.1002/(SICI)1097-0045(19970101)30:1<58::AID-PROS9>3.0.CO;2-H;

        RA   Webber M.M., Bello D., Quader S.T.A.;

        RT   "Immortalized and tumorigenic adult human prostatic epithelial cell

        RT   lines: characteristics and applications Part 2. Tumorigenic cell

        RT   lines.";

        RL   Prostate 30:58-64(1997).

        //

        RX   PubMed=9090379; DOI=10.1038/ng0497-356;

        RA   Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K.A., Lin H.,

        RA   Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T.,

        RA   Frye C., Hu R., Swedlund B., Teng D.H.-F., Tavtigian S.V.;

        RT   "Identification of a candidate tumour suppressor gene, MMAC1, at

        RT   chromosome 10q23.3 that is mutated in multiple advanced cancers.";

        RL   Nat. Genet. 15:356-362(1997).

        //

        RX   PubMed=10702678; DOI=10.1159/000015432;

        RA   Pan Y., Kytola S., Farnebo F., Wang N., Lui W.-O., Nupponen N.,

        RA   Isola J., Visakorpi T., Bergerheim U.S.R., Larsson C.;

        RT   "Characterization of chromosomal abnormalities in prostate cancer cell

        RT   lines by spectral karyotyping.";

        RL   Cytogenet. Cell Genet. 87:225-232(1999).

        //

        RX   PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H;

        RA   Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.;

        RT   "Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon

        RT   12 deletion variant in malignant human ovarian, prostate, and breast

        RT   cancer cell lines.";

        RL   Mol. Carcinog. 28:236-246(2000).

        //

        RX   PubMed=11135431; DOI=10.1002/1098-2264(2000)9999:9999<::AID-GCC1076>3.0.CO;2-E;

        RA   Aurich-Costa J., Vannier A., Gregoire E., Nowak F., Cherif D.;

        RT   "IPM-FISH, a new M-FISH approach using IRS-PCR painting probes:

        RT   application to the analysis of seven human prostate cell lines.";

        RL   Genes Chromosomes Cancer 30:143-160(2001).

        //

        RX   PubMed=11172901; DOI=10.1016/S0165-4608(00)00339-3;

        RA   Strefford J.C., Lillington D.M., Young B.D., Oliver R.T.D.;

        RT   "The use of multicolor fluorescence technologies in the

        RT   characterization of prostate carcinoma cell lines: a comparison of

        RT   multiplex fluorescence in situ hybridization and spectral karyotyping

        RT   data.";

        RL   Cancer Genet. Cytogenet. 124:112-121(2001).

        //

        RX   PubMed=11414198; DOI=10.1007/s004320000207;

        RA   Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H.,

        RA   Wolf E., Gabius H.J.;

        RT   "Comprehensive galectin fingerprinting in a panel of 61 human tumor

        RT   cell lines by RT-PCR and its implications for diagnostic and

        RT   therapeutic procedures.";

        RL   J. Cancer Res. Clin. Oncol. 127:375-386(2001).

        //

        RX   PubMed=12725112; DOI=10.1385/1-59259-372-0:21;

        RA   Russell P.J., Kingsley E.A.;

        RT   "Human prostate cancer cell lines.";

        RL   Methods Mol. Med. 81:21-39(2003).

        //

        RX   PubMed=14518029; DOI=10.1002/pros.10290;

        RA   van Bokhoven A., Varella-Garcia M., Korch C., Johannes W.U.,

        RA   Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.;

        RT   "Molecular characterization of human prostate carcinoma cell lines.";

        RL   Prostate 57:205-225(2003).

        //

        RX   PubMed=15162376; DOI=10.1002/pros.20031;

        RA   Liu A.Y., Brubaker K.D., Goo Y.A., Quinn J.E., Kral S., Sorensen C.M.,

        RA   Vessella R.L., Belldegrun A.S., Hood L.E.;

        RT   "Lineage relationship between LNCaP and LNCaP-derived prostate cancer

        RT   cell lines.";

        RL   Prostate 60:98-108(2004).

        //

        RX   PubMed=15486987; DOI=10.1002/pros.20158;

        RA   Zhao H., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R.,

        RA   Brooks J.D.;

        RT   "Genome-wide characterization of gene expression variations and DNA

        RT   copy number changes in prostate cancer cell lines.";

        RL   Prostate 63:187-197(2005).

        //

        RX   PubMed=22213130; DOI=10.1002/pros.22480;

        RA   Spans L., Atak Z.K., Van Nieuwerburgh F., Deforce D., Lerut E.,

        RA   Aerts S., Claessens F.;

        RT   "Variations in the exome of the LNCaP prostate cancer cell line.";

        RL   Prostate 72:1317-1327(2012).

        //

        RX   PubMed=22278370; DOI=10.1074/mcp.M111.014050;

        RA   Geiger T., Wehner A., Schaab C., Cox J., Mann M.;

        RT   "Comparative proteomic analysis of eleven common cell lines reveals

        RT   ubiquitous but varying expression of most proteins.";

        RL   Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012).

        //

        RX   PubMed=23671654; DOI=10.1371/journal.pone.0063056;

        RA   Lu Y., Soong T.D., Elemento O.;

        RT   "A novel approach for characterizing microsatellite instability in

        RT   cancer cells.";

        RL   PLoS ONE 8:E63056-E63056(2013).

        //

        RX   PubMed=24587179; DOI=10.1371/journal.pone.0090002;

        RA   Spans L., Helsen C., Clinckemalie L., Van den Broeck T., Prekovic S.,

        RA   Joniau S., Lerut E., Claessens F.;

        RT   "Comparative genomic and transcriptomic analyses of LNCaP and C4-2B

        RT   prostate cancer cell lines.";

        RL   PLoS ONE 9:E90002-E90002(2014).

        //

        RX   PubMed=24618588; DOI=10.1371/journal.pone.0091433;

        RA   Chernobrovkin A.L., Zubarev R.A.;

        RT   "Detection of viral proteins in human cells lines by xeno-proteomics:

        RT   elimination of the last valid excuse for not testing every cellular

        RT   proteome dataset for viral proteins.";

        RL   PLoS ONE 9:E91433-E91433(2014).

        //

        RX   PubMed=25485619; DOI=10.1038/nbt.3080;

        RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,

        RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,

        RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,

        RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,

        RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,

        RA   Settleman J., Seshagiri S., Zhang Z.-M.;

        RT   "A comprehensive transcriptional portrait of human cancer cell

        RT   lines.";

        RL   Nat. Biotechnol. 33:306-312(2015).

        //

        RX   PubMed=26256267; DOI=10.1074/mcp.M115.047928;

        RA   Shah P., Wang X., Yang W., Toghi Eshghi S., Sun S., Hoti N., Chen L.,

        RA   Yang S., Pasay J., Rubin A., Zhang H.;

        RT   "Integrated proteomic and glycoproteomic analyses of prostate cancer

        RT   cells reveal glycoprotein alteration in protein abundance and

        RT   glycosylation.";

        RL   Mol. Cell. Proteomics 14:2753-2763(2015).

        //

        RX   PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008;

        RA   Masuishi Y., Kimura Y., Arakawa N., Hirano H.;

        RT   "Identification of glycosylphosphatidylinositol-anchored proteins and

        RT   omega-sites using TiO2-based affinity purification followed by

        RT   hydrogen fluoride treatment.";

        RL   J. Proteomics 139:77-83(2016).

        //

        RX   PubMed=27036029; DOI=10.18632/oncotarget.8456;

        RA   Kregel S., Chen J.L., Tom W., Krishnan V., Kach J., Brechka H.,

        RA   Fessenden T.B., Isikbay M., Paner G.P., Szmulewitz R.Z.,

        RA   Vander Griend D.J.;

        RT   "Acquired resistance to the second-generation androgen receptor

        RT   antagonist enzalutamide in castration-resistant prostate cancer.";

        RL   Oncotarget 7:26259-26274(2016).

        //

        RX   PubMed=27141528; DOI=10.1016/j.dib.2016.04.001;

        RA   Masuishi Y., Kimura Y., Arakawa N., Hirano H.;

        RT   "Data for identification of GPI-anchored peptides and omega-sites in

        RT   cancer cell lines.";

        RL   Data Brief 7:1302-1305(2016).

        //

        RX   PubMed=29233929; DOI=10.1158/0008-5472.CAN-17-1924;

        RA   Horning A.M., Wang Y., Lin C.-K., Louie A.D., Jadhav R.R., Hung C.-N.,

        RA   Wang C.-M., Lin C.-L., Kirma N.B., Liss M.A., Kumar A.P., Sun L.,

        RA   Liu Z., Chao W.-T., Wang Q., Jin V.X., Chen C.-L., Huang T.H.-M.;

        RT   "Single-cell RNA-seq reveals a subpopulation of prostate cancer cells

        RT   with enhanced cell cycle-related transcription and attenuated androgen

        RT   response.";

        RL   Cancer Res. 78:853-864(2018).

        //

        RX   PubMed=29660373; DOI=10.1016/j.bbagen.2018.04.012;

        RA   Touat-Hamici Z., Bulteau A.-L., Bianga J., Jean-Jacques H., Szpunar J.,

        RA   Lobinski R., Chavatte L.;

        RT   "Selenium-regulated hierarchy of human selenoproteome in cancerous and

        RT   immortalized cells lines.";

        RL   Biochim. Biophys. Acta 1862:2493-2505(2018).

        //

        RX   PubMed=30787054; DOI=10.1158/1055-9965.EPI-18-1132;

        RA   Hooker S.E., Woods-Burnham L., Bathina M., Lloyd S.M., Gorjala P.,

        RA   Mitra R., Nonn L., Kimbro K.S., Kittles R.;

        RT   "Genetic ancestry analysis reveals misclassification of commonly used

        RT   cancer cell lines.";

        RL   Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019).

        //

        </pre>'
    headers:
      Connection:
      - Keep-Alive
      Content-Type:
      - text/html; charset=UTF-8
      Date:
      - Tue, 27 Jul 2021 13:58:28 GMT
      Keep-Alive:
      - timeout=5, max=100
      Server:
      - Apache
      Transfer-Encoding:
      - chunked
      Vary:
      - Host
    status:
      code: 200
      message: OK
version: 1
